Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 144 clinical trials
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor

measurable disease
btk inhibitor
bendamustine
anthracyclines
rituximab
  • 23 views
  • 26 Feb, 2022
  • 1 location
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not

  • 0 views
  • 04 Oct, 2022
  • 1 location
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may

platelet count
remission
measurable disease
neutrophil count
venetoclax
  • 0 views
  • 07 Oct, 2022
  • 1 location
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.

  • 0 views
  • 27 Mar, 2021
  • 12 locations
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma

platelet count
cyclin d1
btk inhibitor
mantle cell lymphoma
neutrophil count
  • 174 views
  • 15 Jun, 2022
  • 4 locations
Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

This is a prospective, single-center, single-arm, phase II study of Zanubrutinib-based induction followed by ASCT and Zanubrutinib maintenance (2 years) or followed directly by Zanubrutinib maintenance without ASCT in young and fit patients with untreated MCL. There will be an initial safety run-in phase of 6 patients which will be …

cyclophosphamide
remission
bone marrow infiltration
r-chop
mantle cell lymphoma
  • 0 views
  • 02 Sep, 2021
  • 1 location
Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single agent …

platelet count
cyclin d1
measurable disease
monoclonal antibodies
bendamustine
  • 96 views
  • 13 Oct, 2022
  • 1 location
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The

platelet count
bendamustine
mantle cell lymphoma
gilbert's syndrome
rituximab
  • 0 views
  • 10 Jul, 2022
  • 1 location
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping

cyclin d1
measurable disease
monoclonal antibodies
bendamustine
mantle cell lymphoma
  • 67 views
  • 04 Oct, 2022
  • 303 locations
A Multiple-center Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab in Patients With Previous Untreated Mantle Cell Lymphoma

mantle cell lymphoma. The study includes an induction phase consisting of 12 cycles of ALR. Responding subjects will be eligible to enter a maintenance phase. Subjects will continue maintenance ALR until

platelet count
measurable disease
mantle cell lymphoma
rituximab
neutrophil count
  • 4 views
  • 21 Oct, 2022
  • 1 location